Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report

Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Takumi, Chieko, Tsuji, Taisuke, Hamashima, Ryosuke, Shiotsu, Shinsuke, Yuba, Tatsuya, Urata, Yoji, Hiraoka, Noriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028417/
https://www.ncbi.nlm.nih.gov/pubmed/29988633
http://dx.doi.org/10.1002/ccr3.1627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028417/
https://www.ncbi.nlm.nih.gov/pubmed/29988633
http://dx.doi.org/10.1002/ccr3.1627

Ejemplares similares